Chemoradiation therapy With Cisplatin Versus Cetuximab in Patients With Locoregionally Advanced Head and Neck Squamous Cell Cancer—Mature Results of the ARTSCAN III Trial
The study showed inferior treatment outcomes for cetuximab compared with cisplatin concurrent with RT. Cisplatin remains standard concomitant treatment for locoregionally advanced HNSCC.
Authors
- Signe Friesland (ORCID: https://orcid.org/0000-0001-8118-1066)
- Lalle Hammarstedt‐Nordenvall (ORCID: https://orcid.org/0000-0003-1660-9737)
- Johan Reizenstein
- Per Nilsson (ORCID: https://orcid.org/0000-0002-7983-9778)
- Maria Gebre‐Medhin (ORCID: https://orcid.org/0000-0003-4480-357X)
- Gabriel Adrian (ORCID: https://orcid.org/0000-0001-8837-4696)
- Eva Brun (ORCID: https://orcid.org/0000-0002-5021-7430)
- Björn Zackrisson (ORCID: https://orcid.org/0000-0002-5219-4682)
- Per Engström (ORCID: https://orcid.org/0000-0003-2458-0276)
- Helena Sjödin
- Hedda Haugen Cange
- Edvard Abel (ORCID: https://orcid.org/0000-0002-0482-2015)
- Jan Nyman (ORCID: https://orcid.org/0000-0002-2314-5902)
- Karin Söderkvist (ORCID: https://orcid.org/0000-0002-3683-3763)
- Marcus Thomasson
Institutions
- Karolinska University Hospital (SE)
- Lund University (SE)
- Sahlgrenska University Hospital (SE)
- Karolinska Institutet (SE)
- Örebro University Hospital (SE)
- Skåne University Hospital (SE)
- University of Gothenburg (SE)
- Umeå University (SE)
Publication Details
- Journal
- International Journal of Radiation Oncology*Biology*Physics
- Published
- 2025-06-19
- DOI
- https://doi.org/10.1016/j.ijrobp.2025.05.086
- Citations
- 2
- Primary Topic
- Head and Neck Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 3.70
Funders
- Cancerfonden
- Fru Berta Kamprads Stiftelse